US equities |
SPCX $168.24 ▲+5.83% NVDA $237.40 ▲+1.47% MU $1,065.87 ▼-0.84% TSLA $378.75 ▲+2.20% MSFT $525.63 ▲+1.57% SNDK $1,711.71 ▼-0.48% INTC $117.03 ▼-1.93% META $743.65 ▲+2.14%
FinancialContent

Aktis Oncology, Inc. - Common stock (NQ:AKTS)

18.37 -0.15 (-0.81%)
Delayed Quote Updated: 1:11 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aktis Oncology, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at Upcoming September Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at the BofA Securities Health Care Conference
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at Upcoming March Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
MarketBeat Week in Review – 01/12 - 01/16 ↗
Via MarketBeat
News headline image
A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Webuy Global Shares Spike Higher ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 100 Points; NY Empire State Manufacturing Index Dips In December ↗
 
Via Benzinga
News headline image
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final... 
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
From Akoustis, Inc.
Via Business Wire
News headline image
12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >